Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-NORSE: Anakinra vs Tocilizumab in New-Onset Refractory Status Epilepticus
NCT07281027Phase 3Not yet recruiting
- Sponsor
- Yale University
- Start
- Dec 2026
- Primary completion
- Mar 2030
- Countries
- 7
01
Overview
A Phase 3 trial of anakinra, tocilizumab in status epilepticus (SE), sponsored by Yale University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
anakinratocilizumab
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT07281027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281027.